EpiCor® is an immune stimulant which represents an end product of baker’s yeast (Saccharomyces cerevisiae) fermentation. EpiCor® enhances the ratio of helper to suppressor T lymphocytes (CD4/CD8), stimulates natural cell (NK cell) activity and increases immunoglobulin A (IgA) synthesis. In addition, it possesses antioxidant activity, increases glutathione concentration in erythrocytes and inhibits growth of certain pathogenic microorganisms such as coliform bacteria and Candida.
Potential side effects:
- Have not been reported
Potential drug interactions:
- Allergy to baker’s yeast
Contents: 60 VCaps
The recommended dose of EpiCor® is 1 tablet 2 times a day. Those exceeding the recommended doses must do so under the supervision of their physician due to the increased risk of potential side effects.
Moyad MA, Robinson LE, Kittelsrud JM, Reeves SG, Weaver SE, Guzman AI, Bubak ME. Immunogenic yeast-based fermentation product reduces allergic rhinitis-induced nasal congestion: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2009 Aug;26(8):795-804.
Moyad MA, Robinson LE, Zawada ET, Kittelsrud J, Chen DG, Reeves SG, Weaver S. Immunogenic yeast-based fermentate for cold/flu-like symptoms in nonvaccinated individuals. J Altern Complement Med. 2010 Feb;16(2):213-8.
Schauss, AG, Vodjani, A. Discovery of an edible fermentation product with unusual immune-enhancing properties in humans. FASEB J. 2006; 20(4): A143.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
All information contained on this website is intended for informational and educational purposes only, and is not intended nor suited to be a replacement or substitute for professional medical treatment or for professional medical advice relative to a specific medical question or condition.
- Abnormal Intestinal Microflora
- Irritable Bowel Syndrome
- Leaky Gut Syndrome
- Upper Respiratory Infections/Sinusitis